POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. With fewer than 40 employees, POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company’s drug candidates.

POZEN’s lead product is Treximet™ (formerly known as Trexima™), developed by POZEN in collaboration with GlaxoSmithKline (GSK) for the treatment of acute migraine. Treximet is the brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT _1B/1D agonist formulated with GSK’s RT Technology™, and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID).  Treximet incorporates POZEN’s MT 400 technology, which refers to POZEN’s proprietary combinations of a triptan and an NSAID. The FDA approved Treximet on April 15, 2008 and GSK launched the product in May 2008.

Today, 60 million Americans regularly use NSAIDs to manage their pain.  There are approximately 16,500 deaths and 100,000 hospitalizations yearly resulting from gastrointestinal complications attributed to the use of NSAIDs.  POZEN is responding to this unmet medical need to provide a ”safer NSAID” through its development of a proprietary product candidate, designated PN 400, for the treatment of conditions such as osteoarthritis in patients who are at risk for developing NSAID-associated gastric ulcers.  The PN tablet is designed to contain an immediate release acid inhibitor with a delayed release NSAID in a single dosage form.  The Company signed an exclusive global collaboration agreement in August 2006 with AstraZeneca.  In addition, the company is exploring several combinations of an immediate release acid inhibitor with aspirin, designated PA, that may provide a safer low-dose aspirin therapy for cardiovascular and stroke prevention.